Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 19, 2022 08:30 ET | Source: Celsion Corporation

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...
February 28, 2022 09:00 ET | Source: Celsion Corporation

Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years ...
January 31, 2022 08:00 ET | Source: Celsion Corporation

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 ...
November 29, 2021 08:30 ET | Source: Celsion CORP

Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit

Celsion Corporation’s GEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel...
November 08, 2021 09:00 ET | Source: Celsion CORP

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised...
April 22, 2021 08:30 ET | Source: Celsion CORP

Celsion Management Participates in Alliance Global Partners Virtual Series

LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
November 16, 2020 08:30 ET | Source: Celsion CORP

Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update

Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00...
October 12, 2020 08:00 ET | Source: Celsion CORP

Celsion Corporation Issues Letter to Stockholders

CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...
May 29, 2020 08:30 ET | Source: Celsion CORP

Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer

Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
March 03, 2020 08:30 ET | Source: Celsion CORP

Celsion CEO Issues Letter to Stockholders

LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...